Department of Orthopaedic Surgery, Case Western Reserve University School of Medicine, Cleveland, OH.
Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH.
J Arthroplasty. 2021 Oct;36(10):3513-3518.e2. doi: 10.1016/j.arth.2021.05.026. Epub 2021 May 24.
This study aims to answer the following questions regarding elective total hip arthroplasty (THA): What is (1) the overall 30-day mortality rate; (2) the mortality rate when stratified by age, comorbidities, and preoperative diagnosis; and (3) the distribution of patient demographics, comorbidities, and preoperative diagnoses between the mortality and mortality-free cohorts?
The American College of Surgeons National Surgical Quality Improvement Program database was reviewed for all patients undergoing elective primary THA (2011-2018). A total of 194,062 patients were categorized based on the incidence of 30-day mortality (mortality: n = 206 vs mortality-free: n = 193,856). Patient demographics, comorbidities, and preoperative diagnosis (osteoarthritis [OA] vs non-OA) were recorded. Age category, American Society of Anesthesiologists (ASA) score, and modified Charlson Comorbidity Index (CCI) scores were normalized per 1000 and stratified by preoperative diagnosis.
The 30-day mortality rate was 0.11%. The percentage of deaths per age group (normalized per 1000) was 0% (18-29 years), 0% (30-39 years), 0.049% (40-49 years), 0.052%(50-59 years), 0.071% (60-69 years), 0.133% (70-79 years), and 0.352% (80-89 years). The percentage of deaths per ASA score was 0% (ASA I), 0.035% (ASA II), 0.174% (ASA III), and 1.008% (ASA IV). The percentage of deaths per CCI score was 0.09% (CCI = 0), 0.23% (CCI = 1), 0.74% (CCI = 2), 3.21% (CCI = 3), 4.76% (CCI = 4), and 0.57% (CCI ≥ 5). Non-OA diagnoses were significantly more frequent in the mortality cohort (16.0% vs 7.6%; P < .001).
The risk of mortality was highest in patients aged 80-89, patients of ASA class IV, patients with a CCI score of 4, and patients with a non-OA diagnosis. The overall rate of death was higher in the non-OA cohort compared to the OA cohort.
III.
本研究旨在回答以下关于择期全髋关节置换术(THA)的问题:(1)总体 30 天死亡率是多少;(2)按年龄、合并症和术前诊断分层的死亡率是多少;(3)死亡率和无死亡率队列之间的患者人口统计学、合并症和术前诊断分布如何?
回顾了美国外科医师学会国家手术质量改进计划数据库中所有接受择期初次 THA 的患者(2011-2018 年)。根据 30 天死亡率(死亡:n=206 与无死亡:n=193856)将患者分为两组。记录患者的人口统计学、合并症和术前诊断(骨关节炎[OA]与非 OA)。年龄组、美国麻醉师协会(ASA)评分和改良 Charlson 合并症指数(CCI)评分按每 1000 人进行标准化,并按术前诊断分层。
30 天死亡率为 0.11%。每 1000 人年龄组的死亡率(标准化)分别为 0%(18-29 岁)、0%(30-39 岁)、0.049%(40-49 岁)、0.052%(50-59 岁)、0.071%(60-69 岁)、0.133%(70-79 岁)和 0.352%(80-89 岁)。每 ASA 评分的死亡率分别为 0%(ASA I)、0.035%(ASA II)、0.174%(ASA III)和 1.008%(ASA IV)。每 CCI 评分的死亡率分别为 0.09%(CCI=0)、0.23%(CCI=1)、0.74%(CCI=2)、3.21%(CCI=3)、4.76%(CCI=4)和 0.57%(CCI≥5)。非 OA 诊断在死亡队列中更为常见(16.0% vs 7.6%;P<.001)。
80-89 岁患者、ASA 分级 IV 患者、CCI 评分 4 分患者和非 OA 诊断患者的死亡率最高。非 OA 队列的总死亡率高于 OA 队列。
III。